CD3-binding molecules capable of binding to human and non-human CD3
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 7, 2017
Grant Date -
Apr 10, 2014
app pub date -
May 16, 2012
filing date -
May 21, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully